NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

CMND

Clearmind Medicine Inc

May 16 • 04:00PM ET

0.9900

Dollar change +0.0200
Percentage change 2.06	%

Healthcare • Biotechnology • Canada • NASD

Peers: ATAI MNMD CYBN GHRS EOLS RLMD RLAY CMPS SAVA TCRT

| Held by: PSIL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.31	Insider Own	5.97%	Shs Outstand	4.69M	Perf Week	2.43%
Market Cap	5.08M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.98M	Perf Month	2.06%
Income	-4.96M	PEG	-	EPS next Q	-	Inst Own	18.99%	Short Float	7.86%	Perf Quarter	-29.79%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-25.67%	Short Ratio	1.04	Perf Half Y	-35.29%
Book/sh	0.61	P/B	1.63	EPS next Y	-	ROA	-59.45%	Short Interest	0.23M	Perf Year	-23.26%
Cash/sh	1.15	P/C	0.86	EPS next 5Y	-	ROE	-125.61%	52W Range	0.85 - 2.30	Perf YTD	-28.26%
Dividend Est.	-	P/FCF	-	EPS past 5Y	23.39%	ROI	-173.34%	52W High	-56.96%	Beta	-1.30
Dividend TTM	-	Quick Ratio	1.72	Sales past 5Y	0.00%	Gross Margin	-	52W Low	16.47%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	1.72	EPS Y/Y TTM	95.82%	Oper. Margin	-	RSI (14)	47.59	Volatility	3.66% 7.02%
Employees	-	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	73.52%	Payout	-	Rel Volume	0.15	Prev Close	0.97
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	224.86K	Price	0.99
SMA20	-0.44%	SMA50	-4.13%	SMA200	-22.36%	Trades		Volume	34,206	Change	2.06%

May-12-25 07:32AM	Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction (GlobeNewswire)
Apr-25-25 11:30AM	Psychedelic: Clearmind completes clinical site initiations for AUD trial (TipRanks)
07:59AM	SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders (GlobeNewswire)
07:55AM	Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders (GlobeNewswire)
Apr-23-25 08:25AM	Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites (GlobeNewswire)
09:15AM	Loading…
Apr-21-25 09:15AM	Clearmind Medicine to Host Live Webinar Gazing Through the Crystal Ball Featuring Leading Psychedelic Experts (GlobeNewswire) -6.25%
Apr-17-25 07:38AM	Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior (GlobeNewswire) +15.46%
Apr-16-25 08:40AM	Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism (GlobeNewswire) +5.43%
Apr-11-25 11:05AM	Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial (TipRanks)
Apr-10-25 08:25AM	Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder (GlobeNewswire)
Apr-08-25 06:55AM	Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders (GlobeNewswire)
Apr-01-25 08:15AM	Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment (GlobeNewswire)
Mar-22-25 10:30AM	Psychedelic: Exclusive talk with biotech company Clearmind Medicine (TipRanks)
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks)
09:28AM	Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones (GlobeNewswire)
07:35AM	Loading…
Mar-19-25 07:35AM	Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination (GlobeNewswire)
Mar-18-25 07:32AM	Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients (GlobeNewswire) +5.26%
Mar-14-25 11:40AM	Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial (TipRanks)
Mar-10-25 07:45AM	SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea (GlobeNewswire) +8.49%
07:27AM	Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea (GlobeNewswire)
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks)
Feb-04-25 09:00AM	SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico (GlobeNewswire)
08:35AM	Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico (GlobeNewswire)
Jan-07-25 09:28AM	Clearmind Medicine Announces Shareholders Meeting Results (GlobeNewswire) -5.70%
Jan-06-25 08:15AM	Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment (GlobeNewswire) +6.04%
07:50AM	SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment (GlobeNewswire)
Jan-02-25 07:45AM	Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office (GlobeNewswire) +5.07%
Dec-27-24 07:05AM	Clearmind Medicine to move forward with MEAI-based alcohol substitute (TipRanks)
Dec-26-24 06:59AM	Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute (GlobeNewswire) -9.30%
Dec-24-24 06:55AM	Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial (GlobeNewswire) +40.98%
08:37AM	Loading…
Dec-16-24 08:37AM	Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal Format (GlobeNewswire) -11.08%
Oct-10-24 08:07AM	Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site (GlobeNewswire)
Sep-16-24 04:06PM	SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy (GlobeNewswire)
04:06PM	Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy (GlobeNewswire)
Sep-12-24 08:20AM	Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment (GlobeNewswire)
Sep-06-24 07:55AM	SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment (GlobeNewswire)
07:55AM	Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment (GlobeNewswire)
Aug-29-24 04:25PM	SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination (GlobeNewswire) -6.38%
04:25PM	Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment (GlobeNewswire)
Aug-25-24 09:54AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Aug-21-24 04:11PM	Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment (GlobeNewswire) +6.55% +6.15%
Aug-16-24 04:14PM	Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders (GlobeNewswire)
Aug-06-24 08:57AM	SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug (GlobeNewswire)
08:57AM	Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug (GlobeNewswire)
Jul-31-24 07:44AM	Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research (GlobeNewswire)
Jul-19-24 07:55AM	Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product (GlobeNewswire)
Jul-16-24 09:02AM	Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism (GlobeNewswire) -17.57%
06:03AM	SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss (GlobeNewswire)
06:03AM	Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss (GlobeNewswire)
Jul-12-24 08:02AM	Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine Israel 2024 Conference (GlobeNewswire) +5.59%
Jun-28-24 07:55AM	Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment (GlobeNewswire) +25.37%
Jun-20-24 07:57AM	Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment (GlobeNewswire)
Jun-17-24 11:52AM	CMND Stock Earnings: Clearmind Medicine Reported Results for Q2 2024 (InvestorPlace)
Jun-11-24 07:44AM	Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink (GlobeNewswire)
May-10-24 08:24AM	Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product (GlobeNewswire) -6.67%
May-07-24 07:46AM	Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment (GlobeNewswire) +26.50%
Apr-30-24 04:15PM	Clearmind Applies to Cease Being a Reporting Issuer in Canada (GlobeNewswire)
Apr-17-24 07:49AM	Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders (GlobeNewswire)
Apr-10-24 07:17AM	Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders (GlobeNewswire)
Apr-09-24 08:07AM	Clearmind Medicine CEO Issues Letter to Shareholders (GlobeNewswire) +17.86%
Mar-27-24 09:12AM	Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression (GlobeNewswire)
08:55AM	SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression (GlobeNewswire)
Mar-19-24 07:55AM	Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China (GlobeNewswire)
Mar-13-24 08:14AM	Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial (GlobeNewswire) -7.48%
07:30AM	Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange (GlobeNewswire)
Feb-27-24 07:58AM	SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds (GlobeNewswire)
07:58AM	Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds (GlobeNewswire)
Feb-26-24 10:37AM	Clearmind Medicine receives Patent Approval in China for treatment of binge behaviours (News Direct) -7.98%
Feb-23-24 07:06AM	Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder (GlobeNewswire)
Feb-20-24 07:14AM	SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds (GlobeNewswire) +14.07%
07:14AM	Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds (GlobeNewswire)
Feb-11-24 01:59PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Feb-05-24 07:51AM	Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China (GlobeNewswire)
Feb-01-24 08:15AM	Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center (GlobeNewswire) +20.28%
Jan-16-24 12:20PM	Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND) (ACCESSWIRE) -5.88%
11:19AM	Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement (GlobeNewswire)
Jan-11-24 09:28AM	Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement (GlobeNewswire) -43.00%
08:53AM	Why Is Clearmind Medicine (CMND) Stock Down 24% Today? (InvestorPlace)
Jan-10-24 07:18AM	Clearmind Medicine Completed Type A Meeting with the FDA (GlobeNewswire) +41.55%
Jan-04-24 07:18AM	SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments (GlobeNewswire) -6.51%
07:18AM	Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments (GlobeNewswire)
Dec-14-23 08:26AM	Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards (GlobeNewswire)
Dec-05-23 01:09PM	Why Is Clearmind Medicine (CMND) Stock Up 50% Today? (InvestorPlace) +14.10%
08:47AM	Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment (GlobeNewswire)
Dec-01-23 08:14AM	Weight loss MEAI: Clearmind Medicines Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial (GlobeNewswire) +18.29%
Nov-28-23 08:25AM	Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment (GlobeNewswire) +10.34%
Nov-27-23 08:55AM	Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures (GlobeNewswire) -16.21%
Nov-21-23 08:15AM	Clearmind Medicine Announces 1-for-30 Reverse Share Split (GlobeNewswire)
Nov-17-23 04:15PM	Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance (GlobeNewswire) +7.36% -8.39%
Nov-15-23 07:37AM	Clearmind Medicine Announces Shareholders Meeting Results (GlobeNewswire)
Nov-09-23 09:20AM	Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities (GlobeNewswire) -6.23%
Oct-05-23 09:00AM	Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th (GlobeNewswire) -5.70%
Sep-28-23 09:00AM	Clearmind Medicine to Present at the LD Micro Main Event XVI Investor Conference on October 4th (Newsfile)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-19-23 10:30AM	Aegis Capital Corp. Acted as Exclusive Placement Agent on a $2.25 Million Public Offering for Clearmind Medicine Inc. (NASDAQ:CMND) (ACCESSWIRE)
Sep-18-23 12:16PM	Clearmind Medicine Closes US$2.25 Million Public Offering (GlobeNewswire)
Sep-14-23 09:23AM	Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering (GlobeNewswire) -54.14%
Sep-06-23 09:20AM	Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder (GlobeNewswire) +11.14%
Aug-14-23 08:25AM	Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company (GlobeNewswire) -8.49%
Aug-01-23 09:00AM	SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S. (GlobeNewswire)

Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize it as regulated medicines, foods, or supplements. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CMND

Clearmind Medicine Inc

Upgrade your FINVIZ experience